Reporting Clinical Laboratory Scientist
BillionToOne
Reporting Clinical Laboratory Scientist
BillionToOne
QCT-based molecular diagnostics for prenatal, oncology
Join a team of brilliant, passionate innovators determined to transform healthcare. At BillionToOne, we've built a category-defining, publicly traded company on Nasdaq where transparency fuels trust, collaboration drives breakthroughs, and every contribution moves the needle on our mission to make life-changing diagnostics accessible to all. We don't just aim for incremental improvements; we build products that are 10x better than anything that exists today.
Our scientists, engineers, sales executives, and visionaries are united by an unwavering commitment to changing the standard of care in prenatal and cancer diagnostics. This is where cutting-edge science meets human compassion, and every innovation you contribute helps remove the fear of the unknown from some of life's most critical medical moments.
If you're driven by purpose, energized by innovation, and ready to help shape the future of precision medicine at scale, this is where you belong.
The Prenatal Reporting Clinical Laboratory Scientist (RCLS) contractor is responsible for performing high-complexity clinical laboratory data analysis, reviewing and interpreting molecular diagnostic and sequencing results, and ensuring the accuracy, reliability, and timely reporting of patient results in accordance with established laboratory procedures and applicable regulatory requirements.
The RCLS independently executes validated bioinformatics pipelines, evaluates analytical results and quality control metrics, troubleshoots, and reviews and releases clinical laboratory reports within established authorization and reporting procedures. For complex or unusual results requiring additional evaluation, the RCLS collaborates with Bioinformatics, the Laboratory Directors, and other appropriate clinical personnel to ensure accurate interpretation and reporting.
In addition to routine clinical reporting responsibilities, the RCLS is expected to demonstrate technical leadership by exercising sound scientific judgment, independently investigating complex analytical issues, providing technical guidance to colleagues, supporting personnel training, and identifying opportunities for continuous process improvement. The RCLS may also participate in additional technical leadership activities and cross-functional initiatives as assigned by laboratory leadership.
The RCLS collaborates closely with Laboratory Operations, Bioinformatics, Quality Assurance Management, Genetic Counselors, the Laboratory Directors and other cross-functional teams to support accurate clinical reporting, resolve technical challenges, and maintain efficient laboratory workflows.
The nature of this position requires exceptional attention to detail, strong analytical and problem-solving skills, excellent written and verbal communication, and the ability to manage multiple priorities in a fast-paced clinical laboratory environment. The successful candidate must demonstrate initiative, accountability, adaptability, and the ability to work both independently and collaboratively. This role is a hybrid work arrangement requiring approximately 60% on-site presence at the Union City and/or Menlo Park offices (three days per week on-site and two days per week remote).
Responsibilities:
Clinical Reporting and Quality Review
Quality Assurance and Regulatory Compliance
Process Improvement and Workflow Optimization
Cross-Functional Collaboration and Operational Support
Qualifications:
Benefits And Perks:
For this position, the target hourly rate is: $65 per hour.
BillionToOne is an equal opportunity employer. We do not discriminate on the basis of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status.
For more information about how we protect your information, we encourage you to review our Privacy Policy.
BillionToOne is a next-generation molecular diagnostics company on a mission to make powerful, accurate diagnostic tests accessible to everyone. Our revolutionary QCT molecular counting technology enhances disease detection resolution by over a thousandfold using cell-free DNA,a breakthrough that has already transformed the lives of over half a million patients worldwide.
Unity Complete™ is the only non-invasive prenatal screen capable of assessing fetal risk for both common recessive conditions and aneuploidies from a single maternal blood sample.
Unity Confirm™ enables non-invasive confirmation for high-risk screening results through the capture of intact circulating fetal cells using BillionToOne’s Fetal Cell Capture™ Technology.
Our Northstar® liquid biopsy test uniquely combines treatment selection with real-time monitoring, giving oncologists unprecedented precision in cancer care.
From $0 to $400M+ annualized revenue run-rate in just 6 years. In 2025, we completed one of the most successful IPOs for a medical diagnostics company, building on nearly $400M in private funding,including our $130M Series D in 2024 and backed by world-class investors including Hummingbird, Adams Street Partners, Neuberger Berman, Baillie Gifford, and Premji Invest.
Forbes named us one of America's Best Startup Employers for 2025 and we're Great Place to Work certified, with 100% of our people willing to go the extra mile, even as we've scaled to over 700 employees.
Headquartered in Menlo Park with facilities in Union City, CA, and a new lab opening in Austin, TX in 2027, we're continuing to push the boundaries of what's possible in molecular diagnostics. We're just getting started.
Ready to help us change the world, one molecule at a time? Learn more at billiontoone.com
QCT-based molecular diagnostics for prenatal, oncology
BillionToOne provides molecular diagnostic testing for prenatal screening and cancer monitoring. Its QCT technology detects and measures DNA variations at a single base-pair level, enabling precise analysis across the three billion DNA letters. The main products, Northstar Select and Northstar Response, are tests that help doctors choose the best first-line therapy and track how well treatment is working, respectively. The company markets these services to healthcare providers who perform the tests and use the results to guide patient care. Unlike some rivals, BillionToOne emphasizes high-resolution DNA assessment and scalable diagnostic services through provider partnerships, aiming to improve accuracy, speed, and access. Its mission is to make molecular testing more accurate, efficient, and accessible to all, driven by growth, equality, and teamwork.
Explore more opportunities at BillionToOne